ATE480565T1 - Chimere anti-cd44-antikörper und deren verwendung zur behandlung von akuter myeloischer leukämie - Google Patents

Chimere anti-cd44-antikörper und deren verwendung zur behandlung von akuter myeloischer leukämie

Info

Publication number
ATE480565T1
ATE480565T1 AT04803792T AT04803792T ATE480565T1 AT E480565 T1 ATE480565 T1 AT E480565T1 AT 04803792 T AT04803792 T AT 04803792T AT 04803792 T AT04803792 T AT 04803792T AT E480565 T1 ATE480565 T1 AT E480565T1
Authority
AT
Austria
Prior art keywords
antibodies
acute myeloid
chimere
treatment
myeloid leukemia
Prior art date
Application number
AT04803792T
Other languages
English (en)
Inventor
Florence Smadja
John Dick
Jean Kadouche
Laurence Boumsell
Original Assignee
Inst Nat Sante Rech Med
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Health Network filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE480565T1 publication Critical patent/ATE480565T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04803792T 2003-11-19 2004-11-19 Chimere anti-cd44-antikörper und deren verwendung zur behandlung von akuter myeloischer leukämie ATE480565T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03292873A EP1532984A1 (de) 2003-11-19 2003-11-19 Verwendung von Antikörpern gegen CD44 zur Ausrottung der Stammzellen in akute myeloide Leukämie
PCT/EP2004/014157 WO2005049082A2 (en) 2003-11-19 2004-11-19 Chimeric anti cd44 antibodies and their use for treating acute myeloid leukemia

Publications (1)

Publication Number Publication Date
ATE480565T1 true ATE480565T1 (de) 2010-09-15

Family

ID=34429570

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04803792T ATE480565T1 (de) 2003-11-19 2004-11-19 Chimere anti-cd44-antikörper und deren verwendung zur behandlung von akuter myeloischer leukämie

Country Status (10)

Country Link
US (4) US20050147606A1 (de)
EP (3) EP1532984A1 (de)
JP (1) JP2007513610A (de)
KR (1) KR20060126659A (de)
CN (1) CN1898268A (de)
AT (1) ATE480565T1 (de)
AU (1) AU2004290918B2 (de)
CA (2) CA2484459A1 (de)
DE (1) DE602004029078D1 (de)
WO (1) WO2005049082A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
EP2783700A1 (de) * 2006-09-07 2014-10-01 Stemline Therapeutics, Inc. Auf Krebsstammzellen gerichtete Krebstherapie
EP2526970A1 (de) * 2006-09-07 2012-11-28 Stemline Therapeutics, Inc. Überwachung von Krebsstammzellen
UY30776A1 (es) * 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
EP2009028A1 (de) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Kombination einer konventionellen Antikrebsbehandlung mit einer Verabreichung von Antikörpern gegen CD44 zur Behandlung fester Tumore
CN101368173B (zh) * 2008-04-09 2011-12-28 协和干细胞基因工程有限公司 抗人cd44的工程抗体、载体、试剂盒及其用途
AU2010221168A1 (en) * 2009-03-06 2011-10-06 Angstrom Pharmaceuticals, Inc. Compositions and methods for modulation of cell migration
PT2531527E (pt) * 2010-02-04 2014-05-16 Hoffmann La Roche Anticorpo monoclonal contra cd44 para ser utilizado no tratamento de carcinoma de células escamosas da cabeça e do pescoço
JP2014502258A (ja) * 2010-10-22 2014-01-30 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 免疫反応を抑制するためにプログラムされた制御性ｔ細胞の発見
SG11201401405PA (en) * 2011-10-26 2014-05-29 Univ California Cd44 monoclonal antibody for the treatment of b-cell chronic lymphocytic leukemia and other hematological malignancies
WO2014201417A1 (en) * 2013-06-14 2014-12-18 The University Of Kansas Methods and compositions of modulating tumor initiating cells and the use thereof
NL2011904C2 (en) * 2013-12-06 2015-06-09 Stichting Vu Vumc Leukemic stem cell markers.
WO2019084240A1 (en) * 2017-10-25 2019-05-02 Actinium Pharmaceuticals, Inc. METHODS OF TREATING CANCER USING RADIO-labeled CD45 ANTI-CD45 IMMUNOGLOBULIN AND ADOPTIVE CELLULAR THERAPIES
EP4103610A1 (de) * 2020-02-13 2022-12-21 UCB Biopharma SRL Anti-cd4-ctla4 bispezifische antikörper
CN113552363B (zh) * 2020-04-03 2024-03-08 中国科学院广州生物医药与健康研究院 Cd44作为造血干/祖细胞的标志物及其应用
EP4153192B8 (de) 2020-05-19 2024-09-04 Institut Curie Antagonist des cd44/hyaluronsäure-wegs zur verwendung in einem verfahren zur behandlung des zytokinfreisetzungssyndroms
CA3220458A1 (en) 2021-05-18 2022-11-24 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
CN114213538B (zh) * 2021-12-24 2022-07-08 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用
CN114316049B (zh) * 2021-12-24 2022-08-09 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
IL327045A (en) 2023-10-05 2026-05-01 Capstan Therapeutics Inc Structure-restricted ionizable cationic lipids and lipid nanoparticles
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009811A1 (en) * 1992-10-30 1994-05-11 Duke University An adhesion molecule
FR2715664B1 (fr) 1994-01-31 1996-04-12 Proteine Performance Sa Baculovirus recombinant et son utilisation pour la production d'anticorps monoclonaux.
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
EP0826696B1 (de) * 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
JPH10301492A (ja) * 1997-04-23 1998-11-13 Sony Corp 暗号化装置および方法、復号装置および方法、並びに情報処理装置および方法
KR100653803B1 (ko) * 2000-01-21 2006-12-05 소니 가부시끼 가이샤 데이터 처리 시스템 및 데이터 처리 시스템에서의 데이터 처리 방법
TW538636B (en) * 2000-09-01 2003-06-21 Matsushita Electric Industrial Co Ltd Reproduction equipment, reproduction equipment specifying equipment, reproduction equipment specifying system and methods and recording media for said equipment and system
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
DK1401869T3 (da) * 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1

Also Published As

Publication number Publication date
EP1692183B1 (de) 2010-09-08
CN1898268A (zh) 2007-01-17
EP2275444A1 (de) 2011-01-19
WO2005049082A3 (en) 2005-11-10
KR20060126659A (ko) 2006-12-08
EP1692183A2 (de) 2006-08-23
DE602004029078D1 (de) 2010-10-21
CA2546566A1 (en) 2005-06-02
AU2004290918B2 (en) 2012-03-08
US20050147606A1 (en) 2005-07-07
WO2005049082A2 (en) 2005-06-02
CA2484459A1 (en) 2005-05-19
US20070237761A1 (en) 2007-10-11
US20070184051A1 (en) 2007-08-09
EP1532984A1 (de) 2005-05-25
US20100040540A1 (en) 2010-02-18
AU2004290918A1 (en) 2005-06-02
JP2007513610A (ja) 2007-05-31

Similar Documents

Publication Publication Date Title
DE602004029078D1 (de) Chimere anti-cd44-antikörper und deren verwendung zur behandlung von akuter myeloischer leukämie
GEP20074222B (en) Antibodies to cd40
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
MX9504802A (es) Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.
BR0318454A (pt) anticorpos dirigidos a hormÈnio da paratireóide (pth) e seus usos
DE60235079D1 (de) Gegen menschliches ovarialkarzinom und gegen cd3 gerichteter bispezifischer antikörper
DK1613347T3 (da) Humaniserede antistoffer, der genkender beta-amyloidpeptid
WO2006055638A3 (en) Fully human monoclonal antibodies to il-13
MY176959A (en) Humanized antibodies that recognize beta amyloid peptide
DE60333228D1 (de) Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
DK1827492T3 (da) Antistoffer rettet mod GPNMB og anvendelser deraf
NZ594275A (en) B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
NO20053435L (no) Immunoglobulinvarianter og anvendelser derav
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
DE60239931D1 (de) Kombinationstherapie
GB0016138D0 (en) Organic compounds
BR0207151A (pt) Moléculas de aglutinação terapêuticas
ATE461220T1 (de) Anti-egfr-antikörper
ECSP066432A (es) Moléculas de enlace terapéuticas
DE60238987D1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE69937057D1 (de) Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
ATE478095T1 (de) Konjugate mit einem für die ed-b-domäne von fibronectin spezifischen antikörper, und deren verwendung zum nachweis und zur behandlung von tumoren
WO2004034974A3 (en) Anti-reg iϝ antibody for treatment of colon cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties